S U M M A R Y
The CellaVision TM DM96 is an automated image analysis system dedicated to locating and preclassifying the various types of white blood cells in peripheral blood smears. The system also partially characterizes of the red blood cell morphology and is able to perform platelet counts. We routinely analyzed the blood samples from 440 patients with quantitative and/or qualitative abnormalities detected by the XE-2100 Sysmex TM and manual microscopy for most hematological parameters and accuracy is judged excellent up to 98%. For most common parameters, false positive and false negative ratios are also very good. Whatever the pathology and the number of blasts on smear, all patients were positive for blast detection on DM96
TM
. The system is a useful tool for assisting in the diagnosis and classification of most acute or chronic leukemia. Automatic cell location and preclassification, along with unique cell views on the computer screen, could reduce the time spent performing differentials and make real-time collaboration between colleagues a natural part of the classification process. The workstation also provides an ergonomically correct and relaxed working environment. We suggest its use in routine analysis; the system could be very helpful for the accurate morphological diagnosis of samples from patients with malignant hematological disease. quality stained blood smear preparation for the accurate assessment of cellular morphology. Despite the significant improvements during the last years in hematology analyzers, no significant progress has been made in terms of automatic examination of peripheral blood cells. Irrespective of the analyzer, approximately 15% of the blood samples require manual microscopic observation either because of biological rules or analyzer flags. The relative number of samples to be reviewed will probably not decrease in years to come. Smear examinations are time consuming and require well-trained medical technologists and biologists.
Microscopy automation should be available in hematology laboratories. The decrease of cytology proficiency in the daily practice, the need for development of new innovative techniques in hematology laboratories in the face of limited human resources, and finally, the increase and the complexity of pathologies attributable to population aging create a need for automation of the cytology platform in all laboratories. In this context, we had the opportunity to evaluate the CellaVision TM DM96 automated microscope (CellaVision AB, is a class of cells and objects that the system cannot identify. The system has four flag levels for the following RBC morphological characteristics: polychromasia, hypochromasia, anisocytosis, microcytosis, macrocytosis, and poikilocytosis. Besides the WBCs mentioned above, the operator or 'user' can reclassify 
M A T E R I A L S A N D M E T H O D S

Patients
Four hundred and forty nonselected patients processed with the XE-2100 were analyzed by medical technologists experienced using both conventional microscopy method and DM96
TM . All these samples were abnormal according to routine laboratory criteria and hence, justified a manual smear review (quantitative abnormality, qualitative flag from XE-2100 TM , malignant hematological disease). Under the microscope, 100 leucocytes were observed for establishing the control differential and a mean of 110 leucocytes were required for DM96 TM . To analyze the performance of automated microscopy with DM96
TM and measure its impact on laboratory organization and workflow, we studied its ability to correctly identify blood cells and accuracy compared with manual method and/or XE-2100 TM .
Finally, we analyzed the sensitivity for detection of pathological cells in case of hematological disease.
Efficiency of cell recognition
We analyzed the accuracy in classifying normal and abnormal cells for routine parameters by DM96 
Comparison with manual method
We did not test normal blood samples in this study as this had already been performed and the results showed DM96 TM to be reliable and accurate (Ceelie, Dinkelaar & van Gelder, 2007 
Malignant hematological diseases
We focused then on 84 patients with malignant hematological disorders from various types. The classification of these 84 patients was made according to the WHO criteria (Harris et al.,1999) and is described in 
R E S U L T S Accuracy of cell recognition
Only 2.6% of cells are not identified (especially NRBCs and immature granulocytes) leading the global efficiency of DM96 TM to 95% of direct correct identification. In total, when reclassifying unidentified cells by medical technologist, accuracy is judged excellent up to 98%. For most common parameters, false positive and false negative ratio are very good (Table 2) .
Comparison with manual method
Correlation for DM96 TM results with the manual method and/or XE-2100 TM is excellent for neutrophils, lymphocytes, eosinophils, and acceptable for immature granulocytes, erythroblasts, and for basophils. The correlation observed for monocytes was not as good as expected; both results (DM96 TM and optical manual count) were usually lower than the automatic count but this was not clinically relevant.
Patients with malignant hematological diseases
Patients with blasts on smear
Whatever the pathology (AML, ALL, and CMPD/ MDS) and the number of blasts on smear, all 34 patients were positive for blast detection on DM96 TM .
Additionally, it appears very easy to distinguish myeloid blasts from lymphoid blasts. Despite DM96 TM underestimates the number of blasts cells (especially in ALL where a huge number of them is misclassified as lymphocytes), after manual validation, the Modern characterization of acute malignant hematological disease is a multidisciplinary process. Initially, it requires the integration of clinical, morphological and cytochemical information. A correct and rapid hematological evaluation is necessary to follow-up with the appropriate laboratory tests, specifically immunophenotyping, metaphase cytogenetics and molecular studies. However, the interpretation of morphological and cytochemical stains remains central to the diagnosis and classification of AML. The identification of multilineage dysplasia is entirely dependent on light microscopic assessment of the leukemia cells. Despite the advances in diagnostic technologies, the maintenance and improvement of morphological skills still remain essential requirements in the diagnosis of AML. In case of AML, DM96
D I S C U S S I O N
TM is able to detect blast cells and to identify myeloid blast cells and maturing cells. In addition, it facilitates the evaluation and quantification of dysplasia on a high number of myeloid cells preselected by DM96 TM , which are then classified and eventually properly reclassified by the biologist. In cases of B-ALL and more generally in cases of myeloperoxydase (MPO) negative blast cells, immunophenotyping is always still required for the initial diagnosis. DM96 is also able to detect blast cells but is unable to classify blast cells as lymphoblasts. In this context, it makes sense to rely upon conventional microscopy. If the sample quality is poor, it will be also necessary to survey the entire smear in manual mode. For post-treatment monitoring of patients with malignant hematological disease, DM96
TM represents a good tool for the detection of abnormal cells but is not appropriate for quantifying blast cells in the peripheral blood of patients with B-ALL. In cases of B-CLPD and when operated by an experienced cytologist, DM96 TM is helpful for identifying the disease and especially the lymphoid abnormalities. As an example, we rapidly identified binucleated lymphocytes characteristic of polyclonal lymphocytosis with binucleated lymphocytes (Mossafa et al. 1999) , hairy cells in patients with HCL and atypical lymphocytes in patients with B-CLL. An overview of all lymphoid cells is of great interest in lymphocyte analysis. Finally, DM96 proved to be fully comparable with the manual method in a test using control patient blood smears and in daily practice applicable to >90% of the leucocytes review.
The validation and screening of abnormal smears is one of the core competencies of the technical staff, which is under the supervision of a biologist. For such a routine process, a significant timesaving could be realized by implementing such a reliable automatic system. Therefore, these observations should provide food for thought when considering modalities for improving the efficiency of a hematology laboratory.
The routine introduction of DM96 TM will probably have a great impact on the logistics and organization of both specialized and general hematology laboratories. Depending on the validation requirements and guidelines in each country, all the smears performed by SP-100 TM can be passed onto the DM96 TM in a continuous mode. If, after the unidentified cells have been identified, classified, confirmed and validated, there are no blasts present, the validation could be carried out by the DM96 TM , except when particular difficulties are encountered. For the technical staff, the installation of DM96 TM would have many consequences: the reduction of technical staff time at the microscope while simultaneously increasing the efficiency of the workflow, the elimination of medical technologists facing a difficult diagnosis alone, improved ergonomics of the workstation (elbows, eyes, and back), reduction of the filing of the blades and finally, optimization of time and quality. The introduction of DM96 TM could also optimize the time of the biological staff and improve the proficiency of morphological expertise. In addition, the easy and clear presentation of all patient samples on a computer screen will help ensure the quality of follow-up care in cancer patients. The images can be transmitted to other experts for consultation and confirmation and will facilitate validation of clinical protocols. We also can hope for shorter response times, a reduction in errors, an improvement in continued and advanced education, possibly a redeployment of human resources and a significant cost reduction for a hemogram.
